Compare STKE & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | INMB |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 21 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 45.7M |
| IPO Year | N/A | 2018 |
| Metric | STKE | INMB |
|---|---|---|
| Price | $1.06 | $1.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 417.7K | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $552.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.85 | $1.09 |
| 52 Week High | $7.75 | $3.24 |
| Indicator | STKE | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 45.68 |
| Support Level | $0.90 | $1.23 |
| Resistance Level | $1.42 | $1.76 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 5.64 | 16.00 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.